Market Intelligence, Clinical Progress, and High-Purity Reagents for T-Cell Lymphoma & Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VAV1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VAV1 Recombinant / Mutant Protein (DH-PH domain). Sequence Verified, High Purity (>95%), Theoretical MW confirmed. GEF activity validated by Mant-GTP fluorescence assay. | View VAV1 Products |
| Mutant Control | VAV1 R63A (GEF-dead) / Constitutively Active Mutants. For mechanistic studies and assay validation. Endotoxin <1EU/ug. | View VAV1 Products |
| Gene Delivery | VAV1 Lentivirus Particles. Full-length ORF for stable overexpression in Jurkat or primary T-cells. Purity >95% titration. | View VAV1 Products |
| Benchmark Ab | Anti-VAV1 (Pan-Specific) Recombinant rabbit monoclonal, sequence verified for Western/IP. | View VAV1 Products |
| Validator | VAV1 siRNA Set. For knockdown verification in cell signaling assays. | View VAV1 Products |
| RAC1 | RAC1 GTPase (Active & Inactive Forms). Direct substrate for GEF activity assays; essential for pulldown validation. | View RAC1 Products |
| CDC42 | CDC42 GTPase. Crucial node in VAV1-mediated cytoskeletal rearrangement. | View CDC42 Products |
| ZAP70 | ZAP-70 Kinase. Upstream regulator; critical for TCR signalosome reconstitution studies. | View ZAP70 Products |
| LCP2 | SLP-76 / LCP2 Adapter Protein. Scaffold protein in VAV1 signaling complex; recombinant SH2-domain available. | View LCP2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| VAV1/VAV2/VAV3 Selectivity Screening (High homology across DH domains) | Purified DH-PH domain panels for VAV1, VAV2, and VAV3 available with >95% purity; strict sequence verification by Mass Spec to ensure off-target discrimination. |
| PROTAC Ternary Complex Validation | High-purity VAV1 full-length and domains (SH2/SH3/GEF) expressed in HEK293/E.coli with verified Theoretical MW. |
| Lack of Controls | Matched Wild-Type vs. Catalytically Dead (R63A) mutant pair included for rigorous activity-dependent assay validation. Recombinant antibodies included for robust assay standardization. |
| False Positives in Knockdown | Sequence Verified siRNA included for specificity checks in cell lines. |
| Cell-based TCR Signaling Pathway Analysis | High-titer Lentivirus for stable integration into Jurkat or primary T-cells; preserves native post-translational modification patterns. |
| Protein-Protein Interaction (SLP-76, LAT, ZAP-70) | HEK293 expressed proteins with native glycosylation; suitable for SPR and co-IP studies. |
Live VAV1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VAV1 therapeutics is intensifying, with major players shifting focus from broad immunosuppressants to targeted GEF inhibitors. As first-generation small molecules targeting the DH domain enter preclinical stages, the next wave of R&D is targeting PROTAC-based degradation and allosteric inhibition of the VAV1-Rac1 interface. The target shows particular promise in Peripheral T-Cell Lymphoma (PTCL) where VAV1 mutations drive hyperactivation. In CAR-T therapy optimization, VAV1 signaling thresholds determine efficacy, making it a tuning knob for enhancing persistence and reducing exhaustion. The next wave of R&D is heavily targeting VAV1 degradation pathways to bypass the difficulty of drugging GEF active sites directly.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Emerging Biotech / Academic | PTCL, Autoimmune (SLE) | GEF Activity Assay (Need active DH-PH domain & Mant-GTP readout) |
| PROTAC / Degraders | Early Stage Biotechs; Targeted Protein Degradation focused firms | T-cell Lymphomas (PTCL), Refractory T-Cell Lymphomas | Degradation Assays (Need High-purity WT and Mutant Proteins for binding affinity; need high-titer Lentivirus for stable lines) |
| Cell Therapy (CAR-T Modulation) | CAR-T Developers | B-ALL, DLBCL (efficacy optimization) | TCR Signaling Analysis (Need VAV1 mutants to test signaling thresholds) |
| Allosteric Inhibitors | Structure-based drug design groups | Transplant Rejection | Protein-Protein Interaction Assay (Need full-length & domain truncations) |
| Peptide Inhibitor | Preclinical innovators | Pancreatic Cancer | SH2/SH3 interaction screening (Need specific domain truncations) |